In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deanna Kamienski

Senior Deals Analyst, Strategic Transactions

Deanna has been with Strategic Transactions since 2000. In her role she researches, analyzes, and writes summaries of alliances, M&A, and fundraising activities among global biopharma and medtech companies. Deanna oversees the two Dealmaking columns and authors a Quarterly Statistics article, in addition to contributing content to In Vivo. Prior to joining Strategic Transactions, Deanna worked at Yale University, first in the Office of Medical Development as a gift support services coordinator assisting in fundraising activities and producing fund reports and donor gift acknowledgements. Later she worked at Yale's Department of Epidemiology and Public Health as a research assistant performing various tasks including editing the School of Public Health's website, identifying new funding prospects, providing grant support for the Dean, and preparing development materials and reports. Deanna holds a Bachelor of Science degree from the University of Vermont. In her spare time she enjoys boating and fishing with her family and friends.

Latest From Deanna Kamienski

Deals In Depth: March And April 2020

AstraZeneca and Silence Therapeutics entered a March alliance worth up to $4.08bn for the discovery and development of siRNA drugs for cardiovascular, renal, metabolic and respiratory diseases, while the top April deal was a $3.9bn tie up between Fate Therapeutics and Janssen for iPSC-derived cell-based cancer immunotherapies.

Deals Market Intelligence

Start-Up Quarterly Statistics, Q1 2020

A review of biopharma start-up dealmaking and financing activity from January through March 2020, based on data from Biomedtracker.

Deals Financing

2019 IPOs: Startup Firms Saw Nearly One-Third Of Total Proceeds

Last year, a total of 67 biopharma and medtech companies completed initial public offerings (IPOs), raising for $8.55bn between them.

Commercial Companies

Deals Shaping The Medical Industry, March 2020

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.

Deals Financing

Venture Funding Deals: ALX Oncology, Transcenta Break $100m Barrier With Recent Rounds

Recent venture capital rounds funded the start-ups Airway, Alladapt, ALX Oncology, Azafaros, CANbridge, NeoTx, Spruce and Transcenta.

Financing StartUps and SMEs

Deals Shaping The Medical Industry, February 2020

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.

Deals Financing
See All
UsernamePublicRestriction

Register